Novavax, Canada finalize purchase agreement on COVID vaccine » 17:2401/2201/22/21
Novavax announced that it…
AstraZeneca to slash EU COVID-19 vaccine deliveries by 60% in Q1, Reuters says » 15:2501/2201/22/21
AstraZeneca has informed…
AstraZeneca has informed European Union officials that it would reduce deliveries of its coronavirus vaccine to the bloc by 60% to 31M doses in the first quarter of 2021 due to production issues, Reuters' Francesco Guarascio reports, citing a senior official. The company was forecast to deliver to the 27 EU countries roughly 80M shots by the end of March, the author notes, citing the official who was involved in the talks. Reference Link
AstraZeneca price target lowered to 9,000 GBp from 9,300 GBp at Barclays » 15:0001/2201/22/21
Barclays analyst Emmanuel…
Barclays analyst Emmanuel Papadakis lowered the firm's price target on AstraZeneca to 9,000 GBp from 9,300 GBp and keeps an Overweight rating on the shares.
EU to see delay of AstraZeneca COVID vaccine delivery, FT reports » 11:5301/2201/22/21
The European Union will…
The European Union will experience a delay in the delivery of COVID-19 vaccines made by AstraZeneca in partnership with Oxford, the Financial Times reports. The company said that initial volumes of the vaccine will be "lower than originally anticipated," the report says. Reference Link
AstraZeneca informs EU Commission of vaccine delivery issues, Bild says » 10:3801/2201/22/21
A translation of a…
Marathon Patent Group call volume above normal and directionally bullish » 10:2501/2201/22/21
Bullish option flow…
Bullish option flow detected in Marathon Patent Group with 41,912 calls trading, 1.6x expected, and implied vol increasing almost 8 points to 201.65%. 1/22 weekly 19.5 calls and 1/22 weekly 20 calls are the most active options, with total volume in those strikes near 6,300 contracts. The Put/Call Ratio is 0.27. Earnings are expected on March 23rd.
The Intersection: Crypto and Wall Street This Week » 09:3901/2201/22/21
BTC, BITCOIN, BLK, COIN, CLSK, RIOT, AMD, NVDA, OSTK, IDEX, TEUM, SRAX
As bitcoin, ethereum and…
Sage Therapeutics cut to Market Perform at BMO Capital on valuation » 06:5601/2201/22/21
As previously reported,…
Sage Therapeutics downgraded to Market Perform from Outperform at BMO Capital » 05:0801/2201/22/21
BMO Capital analyst Gary…
BMO Capital analyst Gary Nachman downgraded Sage Therapeutics to Market Perform from Outperform with a $95 price target.
Moderna announces 1st participant dosed in Japan study of Moderna COVID vaccine » 09:0501/2101/21/21
Moderna (MRNA) announced…
Moderna (MRNA) announced that the first participant has been dosed in the Phase 1/2 study of Moderna's vaccine candidate against COVID-19, mRNA-1273 or TAK-919, in Japan, led by Takeda Pharmaceutical (TAK). TAK-919 is Takeda's development code for Moderna's COVID-19 vaccine candidate. "We are pleased that this Phase 1/2 study of our COVID-19 vaccine in healthy adults in Japan has begun. This is the first clinical trial of a Moderna product in Japan and we thank Takeda for partnering with us to potentially protect the Japanese population from COVID-19 with a vaccine," said Stephane Bancel, Chief Executive Officer of Moderna. This placebo-controlled Phase 1/2 study will evaluate the safety and immunogenicity of two vaccinations of mRNA-1273 given 28 days apart. Takeda intends to enroll 200 participants aged 20 years and above in Japan. Each participant will be assigned to receive a placebo or a 100 undefined dose at both vaccinations. Participants will be followed through 12 months after the second vaccination. The ClinicalTrials.gov identifier is NCT04677660. Takeda and Moderna previously announced that Takeda will import and distribute 50 million doses of Moderna's COVID-19 vaccine candidate starting in the first half of 2021, pending licensure in Japan.